No new safety signals were reported with the androgen receptor pathway inhibitor.
Danielle Ternyila
Advertisement
Articles by Danielle Ternyila
Advertisement
Latest Updated Articles
Subgroup data sustain enzalutamide PFS benefit in nmCRPCDecember 7th 2020
Advertisement
Advertisement
Trending on Urology Times
1
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
2
Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution
3
Three-year data show durable responses with mitomycin intravesical solution
4
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
5